JO3336B1 - مركبات أمينو بيريديلوكسي بيرازول - Google Patents

مركبات أمينو بيريديلوكسي بيرازول

Info

Publication number
JO3336B1
JO3336B1 JOP/2015/0235A JOP20150235A JO3336B1 JO 3336 B1 JO3336 B1 JO 3336B1 JO P20150235 A JOP20150235 A JO P20150235A JO 3336 B1 JO3336 B1 JO 3336B1
Authority
JO
Jordan
Prior art keywords
cancer
compounds
aminopyridyloxypyrazole
fibrosis
glioblastoma
Prior art date
Application number
JOP/2015/0235A
Other languages
English (en)
Inventor
Scott Sawyer Jason
Zhao Gaiying
W Beight Douglas
A Coates David
Joseph Sajan
Parthasarathy Saravanan
D Wolfangel Craig
Pei Huaxing
T Mcmillen William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3336B1 publication Critical patent/JO3336B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

يتعلق الاختراع الحالي بمركبات أمينو بيريديلوكسي بيرازول جديدة تثبط نشاط مستقبل بيتا لعامل النمو المتحول 1 (TGF?R1)، وتركيبات صيدلية تشتمل على المركبات، وطرق استخدام المركبات لعلاج السرطان، وبشكل مفضل، سرطان القولون، الميلانوما، كارسينوما الخلايا الكبدية، السرطان الكلوي، الورم الأرومي النخاعي، سرطان البنكرياس، متلازمة خلل التنسج النخاعي، سرطان الرئة، وسرطان معدي، و/أو التليف، وبشكل مفضل، تليف الكبد وداء الكلى المزمن.
JOP/2015/0235A 2014-10-07 2015-09-22 مركبات أمينو بيريديلوكسي بيرازول JO3336B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060724P 2014-10-07 2014-10-07

Publications (1)

Publication Number Publication Date
JO3336B1 true JO3336B1 (ar) 2019-03-13

Family

ID=54266692

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0235A JO3336B1 (ar) 2014-10-07 2015-09-22 مركبات أمينو بيريديلوكسي بيرازول

Country Status (42)

Country Link
US (1) US9617243B2 (ar)
EP (1) EP3204377B1 (ar)
JP (1) JP6043894B2 (ar)
KR (1) KR101921847B1 (ar)
CN (1) CN106795139B (ar)
AP (1) AP2017009836A0 (ar)
AR (1) AR102003A1 (ar)
AU (1) AU2015328553C1 (ar)
BR (1) BR112017005453B1 (ar)
CA (1) CA2961262C (ar)
CL (1) CL2017000765A1 (ar)
CO (1) CO2017002233A2 (ar)
CR (1) CR20170072A (ar)
CY (1) CY1120903T1 (ar)
DK (1) DK3204377T3 (ar)
DO (1) DOP2017000090A (ar)
EA (1) EA031830B1 (ar)
EC (1) ECSP17021097A (ar)
ES (1) ES2700376T3 (ar)
GT (1) GT201700067A (ar)
HR (1) HRP20181797T1 (ar)
IL (1) IL250543B (ar)
JO (1) JO3336B1 (ar)
LT (1) LT3204377T (ar)
MA (1) MA41038B1 (ar)
MX (1) MX367360B (ar)
MY (1) MY190541A (ar)
NZ (1) NZ729800A (ar)
PE (1) PE20170662A1 (ar)
PH (1) PH12017500635B1 (ar)
PL (1) PL3204377T3 (ar)
PT (1) PT3204377T (ar)
RS (1) RS58094B1 (ar)
SG (1) SG11201702481UA (ar)
SI (1) SI3204377T1 (ar)
SV (1) SV2017005411A (ar)
TN (1) TN2017000046A1 (ar)
TR (1) TR201816415T4 (ar)
TW (1) TWI582083B (ar)
UA (1) UA118807C2 (ar)
WO (1) WO2016057278A1 (ar)
ZA (1) ZA201701175B (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
EP3212636B1 (en) * 2014-10-31 2023-11-29 F. Hoffmann-La Roche AG New pyridinyloxy- and phenyloxy-pyrazolyl compounds
JP2019529466A (ja) * 2016-09-30 2019-10-17 イーライ リリー アンド カンパニー 癌の治療における２−｛４−［（４−｛［１−シクロプロピル−３−（テトラヒドロ−２ｈ−ピラン−４−イル）−１ｈ−ピラゾール−４−イル］オキシ｝ピリジン−２−イル）アミノ］ピリジン−２−イル｝プロパン−２−オールの使用
JOP20190080A1 (ar) * 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3600294A4 (en) 2017-03-23 2020-08-26 Clavius Pharmaceuticals, LLC TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND TREATMENT METHODS
WO2019013790A1 (en) * 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS AND USES THEREOF
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
CN107892687B (zh) * 2018-01-21 2018-08-24 广东莱恩医药研究院有限公司 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用
EP3806958B1 (en) * 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
JP7147048B2 (ja) * 2018-08-22 2022-10-04 クラヴィウス ファーマシューティカルズ，エルエルシー Ｔｇｆ－ベータを阻害するための置換イミダゾールおよび処置方法
EP3868755A4 (en) * 2018-10-18 2022-05-25 Nanjing Sanhome Pharmaceutical Co., Ltd. TGF-BETA R1 INHIBITOR COMPOUND AND USE THEREOF
CN112839946B (zh) * 2018-10-31 2022-04-12 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
WO2020103817A1 (zh) * 2018-11-20 2020-05-28 南京圣和药业股份有限公司 TGF-βR1抑制剂及其应用
IL284266B1 (en) * 2018-12-27 2024-02-01 Nexys Therapeutics Inc History of (pyridin-2-yl)amine as an inhibitor of TGF-β in the cell R1 (ALK5) for cancer treatment
EP3908575A4 (en) * 2019-01-10 2022-09-14 Sumitomo Pharma Oncology, Inc. ALK5 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME
WO2020151749A1 (zh) 2019-01-24 2020-07-30 南京明德新药研发有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
JP2022545326A (ja) * 2019-06-25 2022-10-27 インベンティスバイオ カンパニー リミテッド 複素環化合物、その製造方法及びその使用方法
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
CN114728980A (zh) * 2019-12-23 2022-07-08 江苏先声药业有限公司 吡唑类化合物
CN111116565B (zh) * 2020-04-01 2020-07-14 中科利健制药(广州)有限公司 2-芳基-4-（4-吡唑氧基）吡啶类化合物、其制备方法、药物组合物与应用
CN111303135A (zh) * 2020-04-01 2020-06-19 中科利健制药(广州)有限公司 4-（4-吡唑氧基）喹啉类化合物、其制备方法、药物组合物与应用
WO2021204626A1 (en) 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
CN113698395B (zh) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
CN114867723B (zh) * 2020-07-23 2023-05-30 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
WO2023182780A1 (ko) * 2022-03-22 2023-09-28 오토텔릭바이오 주식회사 티아졸 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60221392T2 (de) 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis Neue pyrrolderivate als pharmazeutische mittel
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
UY31281A1 (es) * 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
TW201329067A (zh) * 2011-12-08 2013-07-16 Amgen Inc 作為ｇｋａ活化劑之脲化合物
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds

Also Published As

Publication number Publication date
JP2016535745A (ja) 2016-11-17
CA2961262A1 (en) 2016-04-14
TWI582083B (zh) 2017-05-11
CR20170072A (es) 2017-05-12
PE20170662A1 (es) 2017-05-26
IL250543A0 (en) 2017-03-30
MA41038B1 (fr) 2018-10-31
DK3204377T3 (en) 2018-11-26
MY190541A (en) 2022-04-27
EP3204377B1 (en) 2018-09-26
ES2700376T3 (es) 2019-02-15
TR201816415T4 (tr) 2018-11-21
GT201700067A (es) 2019-10-10
CO2017002233A2 (es) 2017-05-31
HRP20181797T1 (hr) 2018-12-28
WO2016057278A1 (en) 2016-04-14
MA41038A (fr) 2017-08-16
EA201790476A1 (ru) 2017-08-31
AU2015328553B2 (en) 2018-04-12
US9617243B2 (en) 2017-04-11
EA031830B1 (ru) 2019-02-28
DOP2017000090A (es) 2017-04-30
KR101921847B1 (ko) 2018-11-23
UA118807C2 (uk) 2019-03-11
PL3204377T3 (pl) 2019-02-28
TN2017000046A1 (en) 2018-07-04
US20160096823A1 (en) 2016-04-07
ECSP17021097A (es) 2018-02-28
PH12017500635A1 (en) 2017-09-25
BR112017005453B1 (pt) 2022-12-06
AP2017009836A0 (en) 2017-03-31
LT3204377T (lt) 2018-12-27
AU2015328553A1 (en) 2017-03-09
MX2017004457A (es) 2017-06-19
KR20170045348A (ko) 2017-04-26
NZ729800A (en) 2018-07-27
JP6043894B2 (ja) 2016-12-14
TW201623282A (zh) 2016-07-01
CL2017000765A1 (es) 2017-12-15
MX367360B (es) 2019-08-16
RS58094B1 (sr) 2019-02-28
CY1120903T1 (el) 2020-05-29
BR112017005453A2 (pt) 2017-12-12
EP3204377A1 (en) 2017-08-16
PT3204377T (pt) 2018-12-19
CN106795139B (zh) 2019-08-09
BR112017005453A8 (pt) 2018-04-24
SG11201702481UA (en) 2017-04-27
PH12017500635B1 (en) 2017-09-25
CA2961262C (en) 2019-10-22
IL250543B (en) 2020-06-30
AR102003A1 (es) 2017-01-25
SI3204377T1 (sl) 2018-11-30
SV2017005411A (es) 2017-04-21
AU2015328553C1 (en) 2018-11-15
CN106795139A (zh) 2017-05-31
ZA201701175B (en) 2019-01-30

Similar Documents

Publication Publication Date Title
PH12017500635B1 (en) Aminopyridyloxypyrazole compounds
PH12018500457A1 (en) New phenoxymethyl derivatives
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
NZ737399A (en) Ccr2 modulators
JO3155B1 (ar) معدِّل نكهة حلوة
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2016010447A (es) Composiciones y metodos para tratar diabetes y enfermedades hepáticas.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2018001315A (es) Inhibidores de fucosidasa.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
GB201912986D0 (en) Novel drugs for the treatment of metastatic solid tumours
EA201791264A1 (ru) Соединения для лечения злокачественного новообразования
TR201401730A2 (tr) Artroz'un semptomatik tedavisine yönelik bir kompozisyon.